arrow
M

Marianne G. Guren

Oslo University Hospital
H指数:40
被引数:8,179

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ESTRO recommendations for the use, planning and delivery of reirradiation in locally recurrent rectal cancer – Endorsed by ASTRO

欧洲放射肿瘤学会(ESTRO)关于局部复发直肠癌再放疗的使用、规划和实施的建议——经美国放射肿瘤学会(ASTRO)认可

2026-06-270
PRE
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium

寡转移性癌症中针对转移灶的治疗的临床试验终点:一项代表EORTC–ESTRO OligoCare联盟的综述与Delphi共识

2026-04-270
PRE
Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)

肿瘤突变负荷(TMB)、BRAF状态和C反应蛋白(CRP)可预测微卫星稳定(MSS)结直肠癌(CRC)患者对一线奥沙利铂为基础化疗联合纳武利尤单抗的应答。

2024-09-010
PRE
Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

转移性微卫星稳定的BRAF V600E结直肠癌对基于奥沙利铂的一线化疗和免疫检查点阻断的完全反应

2024-06-280
OA
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
2024-04-260
OAAI
Predictive value of tumor mutational burden (TMB) in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) given first-line oxaliplatinbased chemotherapy and immune checkpoint blockade (ICB)
2024-03-220
PRE
A common [18F]-FDG PET radiomic signature to predict survival in patients with HPV-induced cancers
2023-08-264
PRE